Ukraine's national cancer institute providing clinical oncology validation, patient cohort access, and cancer biology expertise for diagnostic and therapeutic research consortia.
Ukraine's national cancer institute is a state clinical and research centre dedicated to oncology, operating at the intersection of cancer biology, diagnostics, and treatment. In EU research projects, they contribute clinical expertise, access to patient cohorts, and oncological validation capabilities — the kind of real-world cancer data that laboratory-only partners cannot provide. Their H2020 participation spans two distinct cancer challenges: non-invasive early detection of gastric cancer using exhaled breath biomarkers, and precision treatment using light-activated antibody-peptide drug conjugates. As a national institution, they carry significant weight as a clinical validation partner for any oncology-related research.
Participated in VOGAS (2019–2022), which screened for gastric cancer using volatile organic compounds in breath — a role that requires direct access to cancer patients and clinical data.
VOGAS used hybrid sensing approaches on exhaled breath, requiring NCI to contribute clinical sample collection and gastric cancer cohort validation.
Joined ALISE (2021–2026), a MSCA-RISE project developing anti-cancer light-controllable antibody-peptide conjugates, signalling engagement with next-generation targeted therapy research.
ALISE focuses on molecular photoswitches and photocontrolled drug candidates specifically for cancer applications, where NCI likely contributes biological and clinical evaluation.
NCI's first H2020 project (VOGAS, 2019) was squarely in cancer diagnostics — using volatile organic compounds in breath to detect gastric cancer early, a non-invasive screening approach. By 2021, their focus shifted from detecting cancer to treating it, through ALISE's work on light-controllable antibody-peptide drug conjugates. This trajectory — from population-level screening tools toward precision, molecularly targeted therapies — mirrors a broader shift in oncology research from early detection to personalised treatment, and suggests NCI is deliberately expanding its research mandate in that direction.
NCI appears to be moving from cancer diagnostics toward precision oncology and targeted drug delivery, making them an increasingly relevant partner for consortia working on smart therapeutics, bioconjugate chemistry, or photomedicine applied to cancer.
NCI has participated exclusively as a consortium partner — never as project coordinator — across both of their H2020 projects. Despite this, they have built a network of 17 unique partners across 12 countries, which for just two projects indicates they join mid-to-large international consortia rather than small bilateral collaborations. This pattern points to a specialist contributor role: they are brought in for their clinical oncology access and validation capabilities, not to lead administrative or scientific coordination.
NCI has connected with 17 distinct partner organisations across 12 countries through just two projects, suggesting participation in genuinely international, multi-partner consortia. No repeated partner patterns are detectable at this scale, indicating broad rather than deep bilateral ties.
As Ukraine's national cancer institute, NCI brings something most academic chemistry or photonics labs cannot: direct access to oncology patients, clinical-grade cancer cohorts, and institutional standing within the national healthcare system. This makes them a high-value validation partner in any project that needs to move from lab to clinic. Their dual engagement — in both diagnostic sensing and targeted drug delivery — means they can contribute meaningfully at multiple points of the cancer care pathway, not just in one niche.
